FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2990783809> ?p ?o ?g. }

• W2990783809 endingPage "199" @default.
• W2990783809 startingPage "191" @default.
• W2990783809 abstract "Previous clinical trials of α7-nicotinic acetylcholine receptor agonists (α7-nAChR agonists) showed mixed results in treating the cognitive and negative symptoms of schizophrenia.To assess the efficacy and safety of α7-nAChR agonists in treating the cognitive and negative symptoms in schizophrenia.A literature search was conducted to identify randomized double-blind placebo-controlled trials for schizophrenia published before May 26, 2017, by searching PubMed, Embase, ClinicalTrials.gov, the Cochrane Library and the Chinese language databases CNKI, Wanfang, and VIP Data. The effects of α7-nAChR agonists were evaluated for overall cognitive function and negative symptoms by calculating standard mean difference (SMDs) between active drugs and placebo added to antipsychotics.8 studies with low bias were included. We found no statistically significant effects of α7 nAChR agonists on the overall cognitive function (SMD=-0.10[-0.46, 0.25], I2 =88%) and negative symptoms (SMD=0.13 [-0.04, 0.30], I2 =64%) in patients with schizophrenia. Sensitivity analysis showed these results to be firm. And this drug is generally safe and well tolerated with no significant difference from placebo based on adverse events (RR=1.02, [0.85, 1.23]) and dropouts (RR=1.04, [0.61, 1.78]) data. Evidence based on outcomes from the meta-analysis was rated as 'moderate' as per the GRADE guidelines.α7-nAChR agonists may not be effective in reversing overall cognitive impairments and negative symptoms in patients with schizophrenia as adjunctive therapies.现有α7- 烟碱型乙酰胆碱受体激动剂(α7-nAChR 受体激动剂) 对精神分裂症的认知障碍和阴性症状治 疗的临床研究结果不尽一致。.评估α7- 烟碱型乙酰胆碱受体激动剂在治疗精 神分裂症认知缺损和阴性症状的临床疗效和安全性。.PubMed、Embase、ClinicalTrials.gov、Cochrane Library 和中国知网、万方、VIP 数据库进行文献检索， 检索时间截止于 2017 年 5 月 26 日。Meta 分析双盲随 机对照试验中α7-nAChR 受体激动剂的作用，评估α7-nAChR 受体激动剂对精神分裂症的总体认知功能和阴 性症状的临床疗效。通过计算药物和安慰剂之间的平 均差(SMDs)，评估α7-nAChR 受体激动剂能否作为有 效的抗精神病药物。.8 个低偏倚研究纳入了meta 分析。我们没有 发现α7 乙酰受体激动剂对精神分裂症患者的认知障 碍 (SMD=-0.10(-0.46,0.25), I2 = 88%) 和阴性症状(SMD =0.13(-0.04,0.30), I2 = 64%) 有明显疗效。敏感性分析也 印证了此结果。药物总体安全且耐受性良好，在不良 事件(RR = 1.02, [0.85, 1.23]) 和脱落率 (RR = 1.04, [0.61, 1.78]) 与安慰剂对照无显著差异。根据GRADE 评级， 该meta 分析结果的证据强度为“ 中”。.α7-nAChR 受体激动剂可能不是有效地改善精神 分裂症患者总体认知障碍和的阴性症状的药物。." @default.
• W2990783809 created "2019-12-05" @default.
• W2990783809 creator A5017557528 @default.
• W2990783809 creator A5022305648 @default.
• W2990783809 creator A5024746005 @default.
• W2990783809 creator A5029269194 @default.
• W2990783809 creator A5033088986 @default.
• W2990783809 creator A5042947456 @default.
• W2990783809 creator A5060396172 @default.
• W2990783809 creator A5061550065 @default.
• W2990783809 date "2017-08-25" @default.
• W2990783809 modified "2023-09-25" @default.
• W2990783809 title "Alpha7 nAChR Agonists for Cognitive Deficit and Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Double-blind Controlled Trials." @default.
• W2990783809 cites W1523031842 @default.
• W2990783809 cites W1694864989 @default.
• W2990783809 cites W1965220974 @default.
• W2990783809 cites W1983282442 @default.
• W2990783809 cites W1988402105 @default.
• W2990783809 cites W1991588393 @default.
• W2990783809 cites W2015219169 @default.
• W2990783809 cites W2017674511 @default.
• W2990783809 cites W2028562300 @default.
• W2990783809 cites W2035367367 @default.
• W2990783809 cites W2050100208 @default.
• W2990783809 cites W2057320515 @default.
• W2990783809 cites W2064739541 @default.
• W2990783809 cites W2092748544 @default.
• W2990783809 cites W2102366253 @default.
• W2990783809 cites W2119605658 @default.
• W2990783809 cites W2120431726 @default.
• W2990783809 cites W2135400982 @default.
• W2990783809 cites W2140042299 @default.
• W2990783809 cites W2142522698 @default.
• W2990783809 cites W2226061200 @default.
• W2990783809 cites W2263665616 @default.
• W2990783809 cites W2290168386 @default.
• W2990783809 cites W2317320523 @default.
• W2990783809 cites W2507697250 @default.
• W2990783809 cites W2570756641 @default.
• W2990783809 cites W2620826610 @default.
• W2990783809 doi "https://doi.org/10.11919/j.issn.1002-0829.217044" @default.
• W2990783809 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5608991" @default.
• W2990783809 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28955138" @default.
• W2990783809 hasPublicationYear "2017" @default.
• W2990783809 type Work @default.
• W2990783809 sameAs 2990783809 @default.
• W2990783809 citedByCount "3" @default.
• W2990783809 countsByYear W29907838092018 @default.
• W2990783809 countsByYear W29907838092021 @default.
• W2990783809 countsByYear W29907838092023 @default.
• W2990783809 crossrefType "journal-article" @default.
• W2990783809 hasAuthorship W2990783809A5017557528 @default.
• W2990783809 hasAuthorship W2990783809A5022305648 @default.
• W2990783809 hasAuthorship W2990783809A5024746005 @default.
• W2990783809 hasAuthorship W2990783809A5029269194 @default.
• W2990783809 hasAuthorship W2990783809A5033088986 @default.
• W2990783809 hasAuthorship W2990783809A5042947456 @default.
• W2990783809 hasAuthorship W2990783809A5060396172 @default.
• W2990783809 hasAuthorship W2990783809A5061550065 @default.
• W2990783809 hasConcept C118552586 @default.
• W2990783809 hasConcept C126322002 @default.
• W2990783809 hasConcept C142724271 @default.
• W2990783809 hasConcept C168563851 @default.
• W2990783809 hasConcept C197934379 @default.
• W2990783809 hasConcept C204787440 @default.
• W2990783809 hasConcept C27081682 @default.
• W2990783809 hasConcept C2776412080 @default.
• W2990783809 hasConcept C2776478404 @default.
• W2990783809 hasConcept C71924100 @default.
• W2990783809 hasConcept C95190672 @default.
• W2990783809 hasConceptScore W2990783809C118552586 @default.
• W2990783809 hasConceptScore W2990783809C126322002 @default.
• W2990783809 hasConceptScore W2990783809C142724271 @default.
• W2990783809 hasConceptScore W2990783809C168563851 @default.
• W2990783809 hasConceptScore W2990783809C197934379 @default.
• W2990783809 hasConceptScore W2990783809C204787440 @default.
• W2990783809 hasConceptScore W2990783809C27081682 @default.
• W2990783809 hasConceptScore W2990783809C2776412080 @default.
• W2990783809 hasConceptScore W2990783809C2776478404 @default.
• W2990783809 hasConceptScore W2990783809C71924100 @default.
• W2990783809 hasConceptScore W2990783809C95190672 @default.
• W2990783809 hasIssue "4" @default.
• W2990783809 hasLocation W29907838091 @default.
• W2990783809 hasOpenAccess W2990783809 @default.
• W2990783809 hasPrimaryLocation W29907838091 @default.
• W2990783809 hasRelatedWork W2139520708 @default.
• W2990783809 hasRelatedWork W2374685850 @default.
• W2990783809 hasRelatedWork W2381982637 @default.
• W2990783809 hasRelatedWork W2393508812 @default.
• W2990783809 hasRelatedWork W2599319608 @default.
• W2990783809 hasRelatedWork W2914141471 @default.
• W2990783809 hasRelatedWork W3013041320 @default.
• W2990783809 hasRelatedWork W3029323012 @default.
• W2990783809 hasRelatedWork W3096683796 @default.
• W2990783809 hasRelatedWork W3213074919 @default.
• W2990783809 hasVolume "29" @default.
• W2990783809 isParatext "false" @default.
• W2990783809 isRetracted "false" @default.

• next